Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluorine F 18 W372 is a radiotracer composed of the compound W372 labeled with the radioisotope fluorine-18. It is designed for use as a positron emission tomography (PET) imaging agent with potential activity for imaging amyloid-beta (Aβ) peptide deposits in the brain. This makes it potentially useful in detecting and evaluating amyloid plaques associated with Alzheimer's disease and related neurodegenerative conditions. The mechanism of action involves binding to amyloid-beta aggregates, allowing visualization via PET scanning due to the radioactive decay of fluorine-18[1][3]. The molecular formula is C14H9FN4OS[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluorine F 18 W372.